Invasive Bladder Cancer Clinical Trial
Official title:
Pilot Testing for Post-Cystectomy mHealth Tool to Improve Perioperative Care
This is a pilot study that involves human subjects undergoing cystectomy surgery for bladder cancer, testing the utilization of a mobile health app that promotes postoperative patient engagement, along with provider monitoring and care. The aim of this pilot study is to assess feasibility and acceptability of an Internet-based mobile health tool following cystectomy discharge. Objectives will be met by assessing weekly adherence, determining acceptability of mobile health questions post-surgery by patients and providers, and by obtaining participant feedback regarding the tool. Complications, re-admissions, and resource utilization will also be monitored throughout the study. The hypothesis is that an mobile health intervention that tracks PROs, provides educational content, and allows real-time feedback via internet-enabled devices has the potential to improve the quality of care delivery and overall patient experience following surgery by decreasing resource utilization and improving symptom control and communication.
Radical cystectomy will be used as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect PRO data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems. The objective is to evaluate the feasibility of pre-specified Patient Reported Outcomes and educational content in an existing mobile health communications platform which tracks patient symptoms and provides real-time feedback to patients and providers following cystectomy discharge. Patient Reported Outcome questions and responses will be inputted using validated questions with branching logic to drive feedback based upon responses. The intent of this study is to evaluate feasibility and acceptability of this mobile health tool following cystectomy discharge. Usual care will continue in coordination with this intervention. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04537221 -
Nordic Cystectomy Study III - Transfusion
|
||
| Completed |
NCT02924480 -
Intravenous Lidocaine for Cystectomy Procedures
|
N/A | |
| Recruiting |
NCT05783271 -
Multiparametric Magnetic Resonance Imaging Performance in Detection of Occult Muscle Invasion in Urinary Bladder Cancer
|
||
| Active, not recruiting |
NCT03702179 -
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
|
Phase 2 | |
| Recruiting |
NCT02560636 -
Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02030574 -
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
|
Phase 2 | |
| Recruiting |
NCT03844256 -
A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04134000 -
Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)
|
Phase 1 | |
| Terminated |
NCT03498196 -
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04523025 -
Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)
|
||
| Recruiting |
NCT04523038 -
Nordic Cystectomy Study II - Albumin
|
||
| Withdrawn |
NCT01922232 -
MRI and Bladder Cancer Chemotherapy
|
N/A | |
| Completed |
NCT03514888 -
HIPEC After Radical Cystectomy for High Risk Bladder Cancer
|
N/A |